CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Site Search
Showing 1 - 4 of 4 results
Press Release
|
|
4 min read
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Press Release
|
|
2 min read
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Press Release
|
|
3 min read
As a clinician, you're critical in helping people with CF maintain their quality of life. We're committed to helping you partner with your patients and their families by providing resources you can use to improve and continue to provide high-quality care.